ascopubs.org

NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening.

Neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial. Late-stage ...
ascopubs.org

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase ...

b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.
ascopubs.org

Long-term follow-up of satricabtagene autoleucel (satri-cel) as sequential therapy after first-line treatment for advanced gastric cancer: A subgroup analysis.

Rab11 family interacting proteins as regulators of T cell recognition and infiltration in triple negative breast cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...
ascopubs.org

Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.

Genomic and transcriptomic correlates of HER3 expression in prostate cancer. Effect of GLP1-1RA exposure compared to DPP-4i exposure on progression of stage I-III cancer to stage IV cancer.
ascopubs.org

Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org

Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org

Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?

Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? The following represents disclosure information provided by authors of this manuscript. All relationships ...
ascopubs.org

Next-Generation Oncolytic Viruses to Overcome Resistance to Anti–PD-1 Therapy in Melanoma

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
ascopubs.org

A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. This is an ASCO ...
ascopubs.org

Mechanisms by Which the Intratumoral Microbiome May Potentiate Immunotherapy Response

Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer D.N.-F. was partially supported by the ...
ascopubs.org

Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.

Comprehensive genomic profiling of advanced anal adenocarcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text ...